Current best evidence on prescribed drugs

Drugdocs Logo

Current best evidence on prescribed drugs

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Adakveo

Chemical Namecrizanlizumab-tmca
Dosage FormInjection (intravenous; 10 mg/mL)
Drug ClassMonoclonal antibodies
SystemBlood
CompanyNovartis
Approval Year2019

Indication

  • Indicated to reduce the frequency of vasoocclusive crises in adults and pediatric patients aged 16 years and older with sickle cell disease.
Last updated on 7/27/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Adakveo (crizanlizumab-tmca) Prescribing Information.2021Novartis Pharmaceuticals Corporation, East Hanover, NJ
Document TitleYearSource
Crizanlizumab for preventing sickle cell crises in sickle cell disease. 2021NICE
Crizanlizumab, voxelotor, and L-glutamine for sickle cell disease: effectiveness and value.2020ICER
Assessment report: Adakveo. 2020EMA
Document TitleYearSource
Systematic review of crizanlizumab: a new parenteral option to reduce vaso‐occlusive pain crises in patients with sickle cell disease.2020Pharmacotherapy
Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis.2020BMJ Open
Antiplatelet agents for preventing vaso-occlusive events in people with sickle cell disease: a systematic review.2019Clinical Advances in Hematology & Oncology
Pharmacotherapeutical strategies in the prevention of acute, vaso-occlusive pain in sickle cell disease: a systematic review.2017Blood Advances
Document TitleYearSource
American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. 2020Blood Advances